Liberate Bio Integrates Quantum-Si’s Next-Generation Protein Sequencing™ Platform to Enhance Gene Therapy Development
Quantum-Si (Nasdaq: QSI) announced that Liberate Bio has integrated the Platinum® Next-Generation Protein Sequencer™ (NGPS) into their platform for developing novel gene therapies. Liberate is using the sequencer's protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, enhancing the precision, speed, and efficiency of their gene therapy discovery and development efforts.
The Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation at single-amino acid resolution. Unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise. The integration has already shown transformative potential, allowing Liberate to accelerate discovery and screening efforts with reduced costs and shortened timelines.
Quantum-Si (Nasdaq: QSI) ha annunciato che Liberate Bio ha integrato il Platinum® Next-Generation Protein Sequencer™ (NGPS) nella loro piattaforma per lo sviluppo di nuove terapie geniche. Liberate sta utilizzando l'applicazione di codifica a barre delle proteine del sequenziatore per eseguire screening dei veicoli di consegna a nanoparticella lipidica in vivo, migliorando la precisione, la velocità e l'efficienza dei loro sforzi di scoperta e sviluppo di terapie geniche.
Il Platinum consente approfondimenti avanzati sul proteoma, fornendo caratterizzazioni della sequenza di proteine e variazioni a risoluzione di singoli aminoacidi. A differenza di approcci alternativi come la spettrometria di massa, non richiede attrezzature costose o competenze specializzate. L'integrazione ha già mostrato un potenziale trasformativo, consentendo a Liberate di accelerare gli sforzi di scoperta e screening con costi ridotti e tempistiche più brevi.
Quantum-Si (Nasdaq: QSI) anunció que Liberate Bio ha integrado el Platinum® Next-Generation Protein Sequencer™ (NGPS) en su plataforma para desarrollar nuevas terapias génicas. Liberate está utilizando la aplicación de código de barras de proteínas del secuenciador para realizar cribados de vehículos de entrega de nanopartículas lipídicas in vivo, mejorando la precisión, velocidad y eficiencia de sus esfuerzos de descubrimiento y desarrollo de terapias génicas.
El Platinum permite obtener información avanzada sobre el proteoma, proporcionando una caracterización de la secuencia y variación de proteínas a resolución de un solo aminoácido. A diferencia de enfoques alternativos como la espectrometría de masas, no requiere equipos costosos ni experiencia especializada. La integración ya ha mostrado un potencial transformador, permitiendo a Liberate acelerar los esfuerzos de descubrimiento y cribado con costos reducidos y plazos más cortos.
Quantam-Si (Nasdaq: QSI)은 Liberate Bio가 그들의 신약 유전자 치료 개발 플랫폼에 Platinum® Next-Generation Protein Sequencer™ (NGPS)를 통합했다고 발표했습니다. Liberate는 단백질 바코딩 응용 프로그램을 사용하여 in vivo에서 지질 나노입자 전달 수단을 스크리닝하여 유전자 치료 발견 및 개발의 정확성, 속도 및 효율성을 향상시키고 있습니다.
Platinum은 단백질 서열 및 변형을 단일 아미노산 해상도로 특성화하여 단백질체에 대한 고급 통찰력을 제공합니다. 질량 분석법과 같은 대안적인 방법과 달리 고가의 장비나 전문 지식이 필요하지 않습니다. 이 통합은 이미 혁신적인 잠재력을 보여주었으며, Liberate가 발견 및 스크리닝 노력을 가속화하고 비용을 줄이며 기간을 단축할 수 있게 하고 있습니다.
Quantum-Si (Nasdaq: QSI) a annoncé que Liberate Bio a intégré le Platinum® Next-Generation Protein Sequencer™ (NGPS) dans sa plateforme de développement de nouvelles thérapies géniques. Liberate utilise l'application de codage de protéines du séquenceur pour effectuer des dépistages de véhicules de livraison de nanoparticules lipidiques in vivo, améliorant la précision, la vitesse et l'efficacité de ses efforts de découverte et de développement de thérapies géniques.
Le Platinum permet d'obtenir des informations avancées sur le protéome, fournissant la caractérisation de la séquence et des variations protéiniques à une résolution de mono-acides aminés. Contrairement aux approches alternatives telles que la spectrométrie de masse, il ne nécessite pas d'équipements coûteux ni d'expertise spécialisée. L'intégration a déjà montré un potentiel transformationnel, permettant à Liberate d'accélérer les efforts de découverte et de dépistage avec des coûts réduits et des délais raccourcis.
Quantum-Si (Nasdaq: QSI) gab bekannt, dass Liberate Bio den Platinum® Next-Generation Protein Sequencer™ (NGPS) in ihre Plattform zur Entwicklung innovativer Gentherapien integriert hat. Liberate nutzt die Protein-Barcoding-Anwendung des Sequenziergeräts, um Lipid-Nanopartikel-Abgabesysteme in vivo zu screenen, wodurch die Präzision, Geschwindigkeit und Effizienz ihrer Entdeckungs- und Entwicklungsbemühungen bei Gentherapien verbessert werden.
Das Platinum ermöglicht fortschrittliche Einblicke in das Proteom, indem es die Charakterisierung von Proteinsequenzen und -variationen mit Auflösung auf einzelnes Aminosäure-Niveau bereitstellt. Im Gegensatz zu alternativen Ansätzen wie der Massenspektrometrie erfordert es keine teuren Geräte oder spezialisiertes Fachwissen. Die Integration hat bereits transformative Potenziale gezeigt, die es Liberate ermöglichen, Entdeckungs- und Screening-Bemühungen mit reduzierten Kosten und verkürzten Zeitrahmen zu beschleunigen.
- Integration of Quantum-Si's Platinum® NGPS into Liberate Bio's gene therapy development platform
- Enhanced precision, speed, and efficiency in gene therapy discovery and development
- Reduced costs and shortened timelines for Liberate Bio's research efforts
- Potential for accelerating drug discovery and development in the pharmaceutical and biotech industry
- None.
Insights
Liberate Bio's integration of Quantum-Si's Platinum® Next-Generation Protein Sequencer™ (NGPS) marks a significant advancement in gene therapy development. This collaboration leverages Quantum-Si's protein barcoding technology to enhance the screening of lipid nanoparticle delivery vehicles, a important component in gene therapy.
The key benefits include:
- Increased precision in delivery and translation efficiency measurements
- Accelerated discovery and development processes
- Potential for cost reduction in gene therapy research
While specific financial figures are not provided, this collaboration has positive implications for both companies. For Quantum-Si (Nasdaq: QSI), the integration of their technology by Liberate Bio represents a tangible commercial application of their Platinum® platform. This could lead to:
- Increased revenue streams from technology licensing or sales
- Enhanced market validation, potentially attracting more biotech partnerships
- Improved investor confidence in Quantum-Si's business model
This collaboration showcases a paradigm shift in protein analysis for gene therapy development. Quantum-Si's technology offers several advantages over traditional methods like mass spectrometry:
- Single-amino acid resolution for precise protein characterization
- Simplified workflow not requiring specialized expertise
- Potential for both in vitro and in vivo applications
Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation, at single-amino acid resolution. Quantum-Si’s protein barcoding application allows researchers to simultaneously tag, track, select, and measure a set of target proteins, with both in vitro and in vivo screening applications. And unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise.
The integration of Quantum-Si’s barcoding application into Liberate’s platform has already shown transformative potential.
“The integration of Platinum’s barcoding application into our workflow represents a significant step forward, allowing us to accelerate our discovery and screening efforts with reduced costs and shortened timelines. This innovation is helping us to push the boundaries of what is possible in the development of targeted genetic therapeutics,” said Walter Strapps, Ph.D., Chief Scientific Officer of Liberate Bio.
Liberate’s work with Platinum underscores the transformative impact that NGPS can have on the pharmaceutical and biotech industry, particularly in gene therapy and drug discovery. “Platinum’s barcoding application is revolutionizing the way researchers approach drug discovery and development. Liberate’s work exemplifies how this technology can unlock new possibilities in drug discovery, driving progress in the field,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si.
About Liberate Bio
Liberate Bio is a leading biotechnology company focused on revolutionizing drug discovery and development. With a commitment to innovation and precision, Liberate Bio utilizes advanced technologies to develop targeted therapeutics that address unmet medical needs. For more information, visit https://www.liberatebio.com/.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904162893/en/
Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is Quantum-Si's stock symbol?
How is Liberate Bio using Quantum-Si's Platinum® Next-Generation Protein Sequencer?
What advantages does Quantum-Si's protein barcoding application offer over mass spectrometry?
How has the integration of Quantum-Si's technology impacted Liberate Bio's research?
